Abstract 6014
Background
The impact of FLT3ITDmut on post-transplant outcome of adult AML remains controversial. A decreased leukemia-free survival (LFS) after allogeneic hematopoietic stem cell transplantation (HSCT) for adult AML in complete remission (CR) was observed in EBMT analysis but not CIBMTR. The impact of FLT3ITDmut on AML patients in later disease stage, as well as the influence of concurrent NPM1 mutation on post-transplant outcome, is less well studied.
Methods
In this study, only adults aged ≥ 18 years with a diagnosis of de novo AML who received allogeneic peripheral blood stem cell transplantation and with known FLT3ITD and NPM1 status in the registry were included. Kaplan-Meier estimates were used to calculate LFS and overall survival (OS). Multivariate analyses for LFS and OS were performed using Cox proportional hazards model.
Results
For patients who received transplant in CR1, the 2 year LFS, OS, and relapse incidence (RI) were 33.1%, 48.7%, and 56%, respectively, for patients of FLT3ITDmutNPM1wt, which are much inferior to patients of FLT3ITDmutNPM1mut (74.3%, 77.8%, and 25.7%, respectively) and patients of FLT3ITDwt (53.5%, 71%, and 37.3%, respectively). In multivariate analysis, patients of FLT3ITDmutNPM1wt, but not patients of FLT3ITDmutNPM1mut, were associated with significant poor LFS (HR 2.672, p = 0.007) and OS (HR 2.439, p = 0.038) compared with patients of FLT3ITDwt. For patients who received transplant after CR1, FLT3ITDmut was associated with significant poor LFS (HR 1.775, p = 0.013) and OS (HR 1.716, p = 0.028) compared with patients of FLT3ITDwt. NPM1 mutation dose not influence the outcome.
Conclusions
For patients in CR1, the impact of FLT3ITD is markedly modified by NPM1 status. The post-transplant outcome remains poor for patients of FLT3ITDmutNPM1wt and highlights the need for a novel approach (such as maintenance FLT3ITD inhibitor after transplant). For patients after CR1, the post-transplant outcome is very poor for patients of FLT3ITDmut and is independent of NPM1 status.
Clinical trial identification
Editorial acknowledgement
The author thanks all the centers participating in the TBMTR. The report is on behalf of the Taiwan society of blood and bone marrow transplantation.
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
592 - Effects of novel targeted anticancer drugs on cytotoxicity, apoptosis, angiogenesis, EMT, drug resistance and autophagic mechanism
Presenter: Seyma Aydinlik
Session: Poster Display session 1
Resources:
Abstract
3235 - Delineating the mechanisms of alpha 1-3 fucosyltransferase FUT11 in ovarian cancer
Presenter: Qi Chen
Session: Poster Display session 1
Resources:
Abstract
3577 - The tyrosine kinase inhibitor Dasatinib blocks tumor growth, invasion and recurrence potential by interrupting the communication between cancer cells and their surrounding microenvironment in triple negative breast cancer
Presenter: Miriam Nuncia-Cantarero
Session: Poster Display session 1
Resources:
Abstract
4808 - NORE1A induces a feedback termination of TNF signaling by antagonizing TNFR1 through ITCH-mediated destruction complex
Presenter: Jieun Ahn
Session: Poster Display session 1
Resources:
Abstract
1294 - Hsp90 inhibitors enhance the antitumoral effect of osimertinib and overcome osimertinib resistance in non-small-cell cell lung cancer cell models
Presenter: Jordi Codony-Servat
Session: Poster Display session 1
Resources:
Abstract
1559 - Expression of IL-17RA promotes cancer stem-like properties of colorectal cancer cells by Stat3 activation
Presenter: Chih-Yung Yang
Session: Poster Display session 1
Resources:
Abstract
1615 - Adaption of Pancreatic Cancer Cells to AKT1 Inhibition Induces the Acquisition of Cancer Stem-Cell Like Phenotype Through Upregulation of Mitochondrial Functions
Presenter: Hugo Arasanz
Session: Poster Display session 1
Resources:
Abstract
4793 - Bub3 is phosphorylated by the Ataxia-Telangiectasia Mutated Kinase in mitosis and required for activation of the mitotic spindle checkpoint in Breast Cancer
Presenter: Mingming Xiao
Session: Poster Display session 1
Resources:
Abstract
1448 - The regulation of INK4 locus by long non-coding RNAs
Presenter: Yojiro Kotake
Session: Poster Display session 1
Resources:
Abstract
1858 - Vascular Endothelial Growth Factor in Colorectal Cancer Pathology, Survival and Treatment
Presenter: Liz Baker
Session: Poster Display session 1
Resources:
Abstract